Jingtai × Xige × Yaosu: Organoids vs Organ-on-a-Chip, the Divide Between Realism and Scalability

I. Conclusion
• SigNature + AetherAI = XtalPi Ecosystem's "High-Fidelity Validation Layer (Wet Lab 2.0)"
• Within the innovative drug ecosystem, it belongs to the "Experimental Validation" stage (AI Design → Experimental Validation → Clinical → Commercialization).

II. Classification
• SigNature: Experimental validation layer (organoids), "Human-like model"
• AetherAI: Experimental validation layer (organ-on-a-chip + AI), "Dynamic human simulation system"

III. SigNature
• Essence: Organoids, patient-derived models, AI-assisted screening
• Capability: Using "miniature human tissues" for drug testing
• Role: Target validation, drug efficacy validation, individual differences
• Synergy within the XtalPi system: XtalPi designs molecules → SigNature validates (more like real patients) → Increases success rate

IV. AetherAI
• Essence: Organ-on-a-chip + AI + automation;
• Capability: Organ-on-a-chip + 3D cells + AI (simulating human organs on chips);
• Advantages over SigNature: Reproducible, standardizable, scalable, and already collaborating with pharmaceutical companies, entering commercialization;
• Synergy within the XtalPi system: XtalPi AI design → AetherAI chip simulation of human response → Efficacy/toxicity prediction

Thoughts: The key ecosystem layer that makes AI results closer to the real human body. SigNature is more realistic, AetherAI is scalable. These two companies address the gap between AI and the human body. This layer determines whether AI drug discovery can be established. Follow-up focus: observe whether AetherAI has entered pharmaceutical companies' standard systems (FDA/EMA), i.e., the ecosystem upgrading from a "tool" to an "industry standard".

$XTALPI(02228.HK)